Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout
Source ↗
👁 0
💬 0
Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s currently in early-stage testing for multiple myeloma.
Comments (0)